Volume 87, Issue 2, Pages (February 2015)

Slides:



Advertisements
Similar presentations
Long-Term Space Flight Simulation Reveals Infradian Rhythmicity in Human Na+ Balance Natalia Rakova, Kathrin Jüttner, Anke Dahlmann, Agnes Schröder, Peter.
Advertisements

Volume 87, Issue 2, Pages (February 2015)
Volume 54, Issue 2, Pages (August 1998)
Volume 62, Issue 3, Pages (September 2002)
Intensive hemodialysis—keeping the faith
Mitchell H. Rosner, W. Kline Bolton  Kidney International 
No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease  Kevin E. Chan, Ravi I. Thadhani,
End-stage renal disease in developing countries
Volume 83, Issue 3, Pages (March 2013)
Red blood cell life span and ‘erythropoietin resistance’
Volume 17, Issue 1, Pages (January 2013)
Volume 66, Issue 4, Pages (October 2004)
Naïve and central memory T-cell lymphopenia in end-stage renal disease
Volume 62, Issue 3, Pages (September 2002)
Seeing the sodium in a patient with hypernatremia
Intensive hemodialysis—keeping the faith
Volume 57, Issue 5, Pages (May 2000)
C-reactive protein and dialysis access
Mortality caused by sepsis in patients with end-stage renal disease compared with the general population  Mark J. Sarnak, Bertrand L. Jaber  Kidney International 
Volume 85, Issue 4, Pages (April 2014)
George A. Kaysen, Burl R. Don
Comorbidity and confounding in end-stage renal disease
Early mortality in dialysis and adequacy of predialysis renal care: the picture is more complex than we thought  Nicolas Rognant, Maurice Laville  Kidney.
Volume 84, Issue 1, Pages (July 2013)
Volume 68, Issue 1, Pages (July 2005)
Volume 87, Issue 2, Pages (February 2015)
Late referral and modality choice in end-stage renal disease
The calcium–phosphorus in guidelines for CKD-MBD
Estimation of Adipose Pools in Hemodialysis Patients From Anthropometric Measures  George A. Kaysen, Peter Kotanko, Fansan Zhu, Shubho R. Sarkar, Steven.
Volume 95, Issue 2, Pages (February 2019)
Volume 70, Issue 12, Pages (December 2006)
Volume 67, Pages S48-S51 (January 2005)
Blood pressure targets in hemodialysis patients
Response to ‘Hepcidin levels in patients with renal disease’
The promise of biomarkers for personalized renal cancer care
Volume 73, Issue 9, Pages (May 2008)
Volume 76, Issue 6, Pages (September 2009)
Volume 76, Issue 3, Pages (August 2009)
Extracorporeal therapy in sepsis: are we there yet?
Alternate-day dialysis may be needed for hemodialysis patients
Volume 66, Issue 1, Pages (July 2004)
Volume 87, Issue 1, Pages (January 2015)
Lynda Anne Szczech, Ira L. Lazar  Kidney International 
A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease  S. Susan Hedayati, Venkata Yalamanchili,
Volume 81, Issue 9, Pages (May 2012)
Prehypertension: is it relevant for nephrologists?
Homocysteine, renal function, and risk of cardiovascular disease
Yasunori Kitamoto, Katsuhiko Matsuo, Kimio Tomita  Kidney International 
Should the targeted value of the phosphate be reviewed in the normal range from the viewpoint of vascular calcification?  Keitaro Yokoyama, Hiraku Yoshida,
Volume 74, Issue 9, Pages (November 2008)
Total hip bone mass predicts survival in chronic hemodialysis patients
The Iranian model of living renal transplantation
Role of sodium in hemodialysis
Volume 80, Issue 10, Pages (November 2011)
Elevated plasma F2-isoprostanes in patients on long-term hemodialysis
Is complement a target for therapy in renal disease?
Volume 68, Issue 1, Pages (July 2005)
Volume 75, Issue 9, Pages (May 2009)
Volume 75, Issue 7, Pages (April 2009)
End-stage renal disease from renal metastases
Changes to the End-Stage Renal Disease Quality Incentive Program
Volume 70, Issue 10, Pages (November 2006)
Antioxidant therapy in hemodialysis patients: a systematic review
Hemodialysis access failure: a call to action—revisited
Where vaptans do and do not fit in the treatment of hyponatremia
A nationwide cohort study suggests chronic hepatitis B virus infection increases the risk of end-stage renal disease among patients in Taiwan  Yi-Chun.
Volume 65, Issue 5, Pages (May 2004)
Volume 87, Issue 6, Pages (June 2015)
Stephen Pastan, J. Michael Soucie, William M. McClellan 
Volume 63, Issue 1, Pages (January 2003)
Presentation transcript:

Volume 87, Issue 2, Pages 434-441 (February 2015) Magnetic resonance–determined sodium removal from tissue stores in hemodialysis patients  Anke Dahlmann, Kathrin Dörfelt, Florian Eicher, Peter Linz, Christoph Kopp, Irina Mössinger, Stephan Horn, Beatrix Büschges-Seraphin, Peter Wabel, Matthias Hammon, Alexander Cavallaro, Kai-Uwe Eckardt, Peter Kotanko, Nathan W. Levin, Bernd Johannes, Michael Uder, Friedrich C. Luft, Dominik N. Müller, Jens M. Titze  Kidney International  Volume 87, Issue 2, Pages 434-441 (February 2015) DOI: 10.1038/ki.2014.269 Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 1 Age-dependent tissue Na+ content and serum vascular endothelial growth factor-C (VEGF-C) levels in patients with end-stage renal disease and in age-matched healthy controls. (Study 1) (a) Muscle and skin Na+ content in younger (<60 years) and older (≥60years) ESRD patients before (green box plot) and after HD treatment (striped green box plot) and in aged-matched normal controls (white box plot). (b) Plasma Na+ and serum VEGF-C levels in the patients (before HD treatment) and the same controls. (c) Relationship between age and skin Na+ content. (d) Relationship between age and circulating VEGF-C levels in controls with normal creatinine levels. (e) Inverse correlation between circulating VEGF-C levels and skin Na+ content in the same controls. Older age was associated with lower VEGF-C levels and with increased tissue Na+ content, suggesting that a reduction in VEGF-C levels may predispose to tissue Na+ accumulation with advancing age. *P(age)<0.05; †P(HD treatment)<0.05; ‡P(controls vs. ESRD patients)<0.05. ESRD, end-stage renal disease; HD, hemodialysis. TE 2.07 ms refers to echo time. Kidney International 2015 87, 434-441DOI: (10.1038/ki.2014.269) Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 2 Study 2: effects of dialysis on muscle and skin Na+. (a) Na+ content in muscle and in skin in 20 hemodialysis (HD) patients before and after HD with the batch dialysis (Genius) system. (b) MRI-determined muscle and skin water (arbitrary units) in the same 20 patients. (c) Relationship between calculated Na+ removal and measured Na+ removal from plasma in the same 20 patients. (d) Relationship between measured Na+ removal from plasma and measured muscle Na+ removal in the same patients. (e) Relationship between measured Na+ removal from plasma and measured skin Na+ removal in the same patients. Kidney International 2015 87, 434-441DOI: (10.1038/ki.2014.269) Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 3 Study 2: represen tative lower limb 23Na magnetic resonance imaging (Na-MRI) images from two end-stage renal disease patients before and after hemodialysis (HD). (a) Patient with high Na+ removal after HD, ultrafiltration rate 2.7l. (b) Patient with low Na+ removal, ultrafiltration rate 3.5l. Standards contain 10, 20, 30, and 40mmol/l Na+. Kidney International 2015 87, 434-441DOI: (10.1038/ki.2014.269) Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 4 Effect of age and circulating serum vascular endothelial growth factor-C (VEGF-C) levels on tissue Na+ content before and after hemodialysis (HD) and on tissue Na+ removal with HD in 33 male end-stage renal disease patients from studies 1 and 2. (a, b) Effect of younger (red) or older (black) age on Na+ content in muscle and in skin and effect of age on Na+ removal (ΔNa+). Younger age leads to lower muscle Na+ content before and after HD therapy and to lower skin Na+ content post HD. (c, d) Effect of lower (green) or higher (black) VEGF-C levels on Na+ content in muscle and in skin and effect of VEGF-C on Na+ removal (ΔNa+). Higher VEGF-C levels are associated with lower tissue Na+ content after dialysis and tend to improve skin Na+ removal with HD. TE 2.07ms refers to echo time. Kidney International 2015 87, 434-441DOI: (10.1038/ki.2014.269) Copyright © 2015 International Society of Nephrology Terms and Conditions